Affordable Access

deepdyve-link
Publisher Website

Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use.

Authors
  • Baxter-Holland, Mia1
  • Dass, Crispin R1, 2
  • 1 School of Pharmacy and Biomedical Science, Curtin University, Perth, WA, Australia. , (Australia)
  • 2 Curtin Health Innovation Research Institute, Perth, WA, Australia. , (Australia)
Type
Published Article
Journal
The Journal of pharmacy and pharmacology
Publication Date
Mar 01, 2018
Volume
70
Issue
3
Pages
320–327
Identifiers
DOI: 10.1111/jphp.12869
PMID: 29355940
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The use of doxorubicin, an antineoplastic medication used for the treatment of cancers via mechanisms that prevent replication of cells or lead to their death, can result in damage to healthy cells as well as malignant. Among the affected cells are mesenchymal stem cells (MSCs), which are involved in the maintenance and repair of tissues in the body. This review explores the mechanisms of biological effects and damage attributed to doxorubicin on MSCs. The PubMed database was used as a source of literature for this review. Doxorubicin has the potential to lead to significant and irreversible damage to the human bone marrow environment, including MSCs. The primary known mechanism of these changes is through free radical damage and activation of apoptotic pathways. The presence of MSCs in culture or in vivo appears to either suppress or promote tumour growth. Interactions between doxorubicin and MSCs have the potential to increase chemotherapy resistance. Doxorubicin-induced damage to MSCs is of concern clinically. However, MSCs also have been associated with resistance of tumour cells to drugs including doxorubicin. Further studies, particularly in vivo, are needed to provide consistent results of how the doxorubicin-induced changes to MSCs affect treatment and patient health. © 2018 Royal Pharmaceutical Society.

Report this publication

Statistics

Seen <100 times